Licensing Portfolio - Enabling Technology
CyMap is a novel CCD-based lens-free imaging system with potential applications in automating a wide-range of live cell-based assays, diagnostic assays or industrial processes. The simple system utilises only low-cost components, is robust and readily miniaturised. Potential applications included tissue culture cell imaging systems, blood cell counting, male fertility testing, pathogen/parasite detection and bioreactor QC. The system has been extensively validated for automating cellular assays including cell division, migration, colony formation and wound healing, as well as for integration with microfluidic platforms. A patent application covering the CyMap technology has been filed and exclusive multi-territory licenses are available to further develop and commercialise the technology in multiple fields. The technology was recently awarded first prize in the Medical and Healthcare category, as well as the overall Grand Prix prize of the prestigious The Engineer’s Technology and Innovation Awards, which recognise and honour innovation in the UK.
Find out more ›
Download PDF of licensing opportunity
A novel, scalable synthetic route has been developed and optimised for the production of synthetic polysaccharides containing the L-iduronate subunit e.g. heparin-type polysaccharides. Reactions at ambient temperature using inexpensive reagents and the key stereochemical step involving purification by crystallization enables large-scale synthesis, facilitating access to larger amounts of various L-iduronate targets. Scalability underpins the potential for viable development of L-ido-containing heparan-related saccharides for clinical evaluations. The patent portfolio is available for licensing in the fields of research tools and therapeutic development outside of CRT’s Oligosaccharides as Inhibitors of Angiogenesis programme.
Find out more ›
Download PDF of licensing opportunity
Inducible Cre transgenic strains expressing the Cre-ER(T2) gene switch under the control of VECAD or BMX promoters. These mice can be crossed with mice carrying LoxP-flanked genes of interest to generate temporally controlled tissue-specific deletions upon tamoxifen treatment. Tamoxifen treatment of the VECAD-Cre-ER(T2) embryos induces Cre activity in >90% of endothelial cells of all arteries, veins and in the lymphatic system. Tamoxifen treatment of adult mice induces Cre activity only in smaller vascular beds. These mice may be used for study of genes involved in vascular development and pathological angiogenesis in adult mice. Tamoxifen treatment of the BMX-Cre-ER(T2) mice induces Cre activity in arterial but not venous endothelial cells. These mice may be useful for study of genes involved in pathological arterial conditions, including artherosclerosis.
Find out more ›
Download PDF of licensing opportunity
A novel cell surface marker that is able to determine both the pluripotency and early differentiation state of an ES cell population in a single, rapid, non-destructive assay. This marker is a valuable tool for a wide range of ES cell techniques. Well characterised monoclonal antibodies to mouse and human antigens are available.
Find out more ›
Download PDF of licensing opportunity
Small molecules as reagents have many and varied uses. Due to the ability to design molecules they can be more useful for research than some other molecules. We are pleased to present the datasheet for Lomeguatrib - a specific and highly potent inactivator of of the DNA repair protein MGMT and related mammalian proteins.
Find out more ›
Download PDF of licensing opportunity
A mouse model has been developed, in which cytochrome b5 has been knockout in the liver. The loss of cytochrome b5 results in significant reduction of the P450 metabolism and the development of hepatic vesicular steatosis. The model phenocopies the genesis and progression of non-alcoholic steatosis. This model is a valuable tool for the studying of the role of cytochrome b5 in steatosis and the evaluation of new prophylactics or therapeutics for steatosis.
Find out more ›
Download PDF of licensing opportunity
A mouse model has been developed, in which cytochrome b5 has been knockout in the liver. The loss of cytochrome b5 results in significant reduction of drug metabolism. This model is a valuable tool for the studying of cytochrome b5 in metabolism and the evaluation of drug efficacy, bioavailability and toxicity
in vivo. Liver cells extracted from the mice (hepatic microsomes) could also be isolated and used to test new drugs
in vitro.
Find out more ›
Download PDF of licensing opportunity